TWST — Twist Bioscience Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1581280 ·
Last close
$112.00
Market Cap
$7.43B
52W High
$219.71
52W Low
$24.41
ADV30
2,655,785
Next earnings
2027-02-01
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 118,376,000 | 62,454,000 | -36,280,000 | -35,051,000 | 672,437,000 | 117,436,000 | 226,698,000 |
| Mar 2026 | 110,715,000 | 57,122,000 | -38,658,000 | -44,021,000 | 676,214,000 | 122,670,000 | 221,120,000 |
| Dec 2025 | 103,698,000 | 53,972,000 | -33,100,000 | -30,507,000 | 638,085,000 | 148,591,000 | 181,990,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-53,072,000
Investing CF
$-45,240,000
Financing CF
$13,797,000
CapEx
$-40,151,000
Dividends Paid
—
Buybacks
$-18,000
EPS Diluted TTM
$-2.22
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,429,157,000
Inventory
$35,162,000
Receivables
$87,581,000
ST Investments
$49,403,000
EBIT TTM
$-137,972,000
Pretax Income TTM
$-135,853,000
Interest Exp TTM
$143,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$431,798,016
EBITDA
$-115,282,000
Free Cash Flow
$-64,822,500
Enterprise Value
$7,919,389,696
Total Cash
$166,839,008
Total Debt
$108,590,000
Shares Out
66,301,174
Trailing EPS
$-2.22
Book Value
$7.11
ROE
-29.6%
ROA
-13.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 459,433,000 | -132,250,000 | -130,202,000 | 1,121,808,000 | 233,792,000 | 888,016,000 | -41,431,000 |
| Sep 2025 | 376,572,000 | -136,259,000 | -77,670,000 | 641,861,000 | 168,903,000 | 472,958,000 | -47,628,000 |
| Sep 2024 | 312,974,000 | -175,901,000 | -208,726,000 | 614,323,000 | 141,634,000 | 472,689,000 | -64,094,000 |
| Sep 2023 | 245,109,000 | -206,903,000 | -204,618,000 | 776,403,000 | 152,971,000 | 623,432,000 | -142,474,000 |
| Sep 2022 | 203,565,000 | -249,021,000 | -217,863,000 | 961,378,000 | 171,993,000 | 789,385,000 | -124,385,000 |
TTM Snapshot
Revenues TTM
$431,798,000
NetIncome TTM
$-136,717,000
OpCashFlow TTM
—
Assets (Latest)
$672,437,000
Forward EPS
$-0.63
Max Pain — expiry 2026-12-18
max pain strike: $145.00 · spot: $116.35 · call oi: 3,257 · put oi: 2,636
Expected Move to 2026-12-18:
±$24.55
(21.10%) —
implied range
$91.80 –
$140.90
· ATM straddle on $115.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGON | CG Oncology, Inc. | $7.00B | $78.94 | — |
| IMVT | Immunovant, Inc. | $6.87B | $33.21 | — |
| IBRX | ImmunityBio, Inc. | $6.66B | $6.26 | — |
| KOD | Kodiak Sciences Inc. | $6.33B | $96.80 | — |
| KRYS | Krystal Biotech, Inc. | $8.85B | $298.55 | — |
News headlines (Yahoo Finance, 1h cache)
Twist Bioscience Corporation Q4 2026 Earnings Call Summary
2026-11-12 22:15 · Yahoo
This Biotech's Guidance Seemingly Beat Expectations — But A Twist Slammed The Stock
2026-11-12 21:16 · Yahoo
Twist Bioscience Q4 Earnings Call Highlights
2026-11-12 21:14 · Yahoo
Twist Bioscience: 3 Key Takeaways for Long-Term Investors
2026-11-12 21:09 · Yahoo
Twist Bioscience earnings analysis: questions answered and next catalysts
2026-11-12 20:59 · Yahoo
Twist Bioscience (TWST) Q4 2026 Earnings Call Transcript
2026-11-12 19:45 · Yahoo
Full-Year Revenue Guidance and Strong Quarter Drove Twist Bioscience Corporation (TWST) Higher in Q3
2026-11-12 15:07 · Yahoo
Twist Bioscience: Fiscal Q4 Earnings Snapshot
2026-11-12 13:40 · Yahoo
Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates
2026-11-12 13:35 · Yahoo
Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
2026-11-12 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.